Where to buy Pfizer stock: it is in the green again despite rumors of delisting from NYSE

While the majority of stocks in the United States take a hit from the rising inflation in the US, Pfizer stock has registered a 1.42% gain today despite having to contend with rumors of being delisted from the New York Stock Exchange.

To help stock traders eying the Pfizer stock, Invezz has created a brief article on what it is and the best places to buy it.

Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

To find out more, please continue reading.

Best places to trade Pfizer Stock

eToro

eToro is one of the world’s leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It’s social copy trading features make it a great choice for those getting started.

Register with eToro instantly

Disclaimer

Firstrade

Firstrade is a leading online brokerage firm offering a full line of investment products and tools designed to help investors like you take control of your financial future. Since its founding in 1985, Firstrade has been committed to providing high value and quality services to help you reach your financial goals.

Register with Firstrade instantly

What is Pfizer stock?

Pfizer stock is the stock of Pfizer Inc. and it trades on New York Stock Exchange under the symbol NYSE: PFE.

Pfizer Inc. is an American multinational biotechnology and pharmaceutical company that is among the corporations that are actively participating in the production of Covid-19 vaccines and treatment pills.

Pfizer was established in 1849 and is headquartered in Manhattan, New York City.

Should I buy the PFE stock today?

If you are looking for a stock that has surged today, then the Pfizer stock is a good choice.

Nevertheless, the stock has dipped since December 31, 2021 a situation that is being complicated by the ongoing rumors that it applied to be delisted from the New York Stock Exchange.

Pfizer stock price prediction

There were high expectations that the Pfizer stock could close the year above $63 especially after the boost it received by FDA Approved the company’s at-home Covid treatment pill, Paxlovid.

However, that did not materialize. Instead, the stock took a dive to its current price about $49.90 and analysts are neutral on its next move. Some foresee a comeback above $50 while others believe the bear is far from over.